Mark Schenerman

Dr. Mark Schenerman is currently Senior CMC Advisor for Science/Technology/Strategy at Novavax. Prior to this, he was President of a consulting firm (CMC Biotech-MAS Consulting) that he founded and was advising academic, industry, and regulatory agency groups. He is an experienced biopharmaceutical scientist and executive who has most recently been responsible for developing and aligning cross-functionally Chemistry, Manufacturing, & Control (CMC) strategy leading to global regulatory filings (IND through BLA) at MedImmune/AstraZeneca. Dr. Schenerman was also responsible for maintaining and building key collaborations externally with peer biopharmaceutical companies, academic institutions, and government agencies to advance regulatory science. Prior to this, Dr. Schenerman headed an R&D group that performed physicochemical and biological characterization of preclinical and clinical products, stability and release testing, technology transfer to quality control and ongoing product development support. Since joining MedImmune in 1994, Dr. Schenerman played an integral role in developing and leading the company’s Analytical Biochemistry function, supporting all stages of product development. Prior to joining MedImmune, Dr. Schenerman held positions in biologics development and research and development at Bristol-Myers Squibb Company and was a post-doctoral associate at Cornell University. He earned his Bachelor’s degree in Medical Technology at the University of Maryland and his doctorate in Biochemistry and Molecular Biology at the University of Florida.